1.59 USD
▼-0.02-1.24%
盘后 1.70 +6.92%
2026-09-15
市值
$182.12M
市盈率
—
EPS
-1.04
股息率
—
52 周区间
1.46 – 6.79
成交量
279.51K
Beta
1.50
目标价
8.67
52W 低 1.4652W 高 6.79
价格走势
公司简介
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab a...